Bahar Irit, Kaiserman Igor, McAllum Penny, Rootman David, Slomovic Allan
Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.
Curr Eye Res. 2008 Jan;33(1):23-8. doi: 10.1080/02713680701799101.
We report on the use of subconjunctival bevacizumab on corneal vessel density in recurrent pterygia.
The charts of 5 patients with recurrent pterygium, who received subconjunctival injections of bevacizumab (2.5 mg/0.1 ml) were retrospectively reviewed. Ophthalmic evaluation included Snellen visual acuity (VA), tonometry and complete examination before the injection and at 1 week and 1 and 3 months thereafter. Digital photographs of the eyes were analyzed by image analysis software to determine the area of cornea covered by new vessels as a percentage of the total corneal area.
No ocular or systemic adverse events were observed. No change in visual acuity was noted in any patient following the injection. The mean change in corneal vascularization after one bevacizumab injection was 0.03%+/-0.45, while after two injections the change was 0.025%+/-0.19 (both not statistically different than zero, t-test).
Short-term results suggest that subconjunctival bevacizumab is well tolerated but does not cause regression of corneal vessels in recurrent pterygium.
我们报告结膜下注射贝伐单抗对复发性翼状胬肉角膜血管密度的影响。
回顾性分析5例接受结膜下注射贝伐单抗（2.5mg/0.1ml）的复发性翼状胬肉患者的病历。眼科评估包括注射前、注射后1周、1个月和3个月时的Snellen视力（VA）、眼压测量及全面检查。通过图像分析软件对眼部数码照片进行分析，以确定新生血管覆盖的角膜面积占角膜总面积的百分比。
未观察到眼部或全身不良事件。注射后所有患者视力均无变化。单次注射贝伐单抗后角膜血管化的平均变化为0.03%±0.45，两次注射后变化为0.025%±0.19（两者与零相比均无统计学差异，t检验）。
短期结果表明，结膜下注射贝伐单抗耐受性良好，但不会使复发性翼状胬肉的角膜血管消退。
